PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Phase 2

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Etrasimod

First Posted Date: 2022-03-18

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT05287126

Locations: 🇵🇱
Centrum Zdrowia MDM, Warszawa, Poland
🇸🇰
Narodny ustav detskych chorob, Bratislava, Bratislavský KRAJ, Slovakia
🇺🇸
Arkansas Children's (IP Address), Little Rock, Arkansas, United States

and more 44 locations

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Completed

Conditions: Chronic Myeloid Leukaemia

First Posted Date: 2022-03-18

Last Posted Date: 2023-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 1484

Registration Number: NCT05286528

Locations: 🇭🇺
Pfizer, Budapest, Hungary

A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07265803

First Posted Date: 2022-03-18

Last Posted Date: 2024-03-29

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT05286281

Locations: 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States

Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: NaxRedy ™
Drug: Naloxone Hydrochloride Injection, USP

First Posted Date: 2022-03-03

Last Posted Date: 2022-03-03

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT05264493

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: PF-07321332/ritonavir
Drug: PF-07321332

First Posted Date: 2022-03-03

Last Posted Date: 2022-06-30

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05263895

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: PF-07321332/ritonavir

First Posted Date: 2022-03-03

Last Posted Date: 2024-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05263921

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Drug: nirmatrelvir / ritonavir

First Posted Date: 2022-03-03

Last Posted Date: 2024-05-30

Lead Sponsor: Pfizer

Target Recruit Count: 3346

Registration Number: NCT05263908

Locations: 🇯🇵
Pfizer Local County, Tokyo, Japan

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinoma
Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: maplirpacept (PF-07901801)
Drug: Pegylated Liposomal Doxorubicin (PLD)

First Posted Date: 2022-03-02

Last Posted Date: 2024-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05261490

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸
oncology Consultants, P.A., Houston, Texas, United States
🇺🇸
Oklahoma Cancer Specialist and Research Institute. LLC, Tulsa, Oklahoma, United States

and more 12 locations

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Phase 3

Recruiting

Conditions: COVID-19

Interventions: Drug: nirmatrelvir
Drug: ritonavir

First Posted Date: 2022-03-02

Last Posted Date: 2025-05-04

Lead Sponsor: Pfizer

Target Recruit Count: 160

Registration Number: NCT05261139

Locations: 🇧🇬
DCC "Alexandrovska", Sofia, Bulgaria
🇧🇬
Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria
🇲🇽
Fundación Santos y De la Garza Evia, Monterrey, Nuevo LEÓN, Mexico

and more 72 locations

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Phase 1

Active, not recruiting

Conditions: Breast Cancer
Solid Tumors

Interventions: Drug: PF-07220060 + PF-07104091 combination dose escalation
Drug: PF-07104091 + PF-07220060 + letrozole dose expansion
Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion

First Posted Date: 2022-03-02

Last Posted Date: 2024-11-18

Lead Sponsor: Pfizer

Target Recruit Count: 240

Registration Number: NCT05262400

Locations: 🇺🇸
Administrative Address: UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States

and more 46 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy